Exelixis Joins Fight Colorectal Cancer with a Strong Arm Selfie - OncoDaily Exelixis Joins Fight Colorectal Cancer with a Strong Arm Selfie / cancer, colorectal cancer, Colorectal Cancer Awareness Month, Exelixis, OncoDaily, Oncology,

Exelixis Joins Fight Colorectal Cancer with a Strong Arm Selfie

@fightcrc.bsky.social

oncodaily.com/voices/fight...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #OncoDailyGI #GIOncology

During #ColorectalCancerAwarenessMonth, stay current on evolving GI oncology data.

Join the Best of GU & GI Cancers Conference 2026.

📄 Download the full agenda:
https://bit.ly/40b5LPY

#GIOncology #CancerEducation #CME

Microbiota‑based strategies, diet, probiotics, prebiotics, FMT, are emerging as potential tools to personalize nCRT. More clinical validation is needed, but the field is rapidly expanding.
#RectalCancer #GIOncology #Microbiome

🔗 Read more: bit.ly/ONCOnews22J-02

#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerResearch #GIOncology #ClinicalTrials

Save the Date! Join us for the first Y-InSiGHT webinar on career development for emerging professionals in hereditary GI tumours.

📅 28 January | 🕒 14:00 CET | 💻 Online

Register now and find more info 👉 shorturl.at/k773K

#YInSiGHT #HereditaryCancer #Genetics #GIOncology #EarlyCareerResearchers

Pelareorep Plus Atezolizumab Drives Responses in Third-Line Squamous Cell Anal Carcinoma | OncLive Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

Pelareorep Plus Atezolizumab Drives Responses in Third-Line Squamous Cell Anal Carcinoma #onoclogy #GIoncology

www.onclive.com/view/pelareo...

🔗 Read more: bit.ly/ONCOnews09J-04

#ONCOnews #OncoAlert #OncEd #GIOncology #ClinicalTrials #CancerResearch

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors | OncLive PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors #oncology #lcsm #GIoncology
www.onclive.com/view/pln-101...

Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology

HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG

Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I

for the OncoAlert TOP3 Series post ESMO 2025, more to come..

✅NICHE2
✅STELLAR 303

Annual Scientific Meeting The AGITG Annual Scientific Meeting provides GI cancer researchers and specialists the opportunity to present recent research into GI cancers and discuss current challenges and potential solutions…

🧬 There's still time to register for the #AGITG 27th Annual Scientific Meeting — 24-27 November 2025 in Tarntanya / Adelaide: t.ly/nCn4Y

You can learn more about the program highlights in our Special Preview podcast here: t.ly/ly9fx #GICancer #GIOncology #CancerResearch #Collaboration #MedEd

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC | OncLive Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC @myesmo.bsky.social #ESMO25 #GIoncology #oncology

www.onclive.com/view/checkma...

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer | OncLive Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer @myesmo.bsky.social #ESMO25 #GIoncology #oncology

www.onclive.com/view/bemarit...

🏆 Discover how this award-winning project on target & OAR definition in rectal HDR brachytherapy, honoured at #ESTRO25, aims to standardise care and improve outcomes in rectal cancer treatment.
👉 bit.ly/3TXTYRU
#Brachytherapy #GIoncology #RadiationOncology #OrganPreservation #rectalcancer

📢 At #ESMOGI25 today:
EORTC hosts a special session with 5 expert lectures + Q&A on neoadjuvant advances, organ preservation & novel targets in GI oncology (16:30–18:00, Room Valencia).

Also: 2 poster displays from 15:30–16:30 (Foyer).

@myesmo.bsky.social #EORTCgastrointestinal #GIOncology

Redefining cancer care: the case for an onco-gastroenterology subspecialty - Nature Reviews Gastroenterology & Hepatology Onco-gastroenterology is defined as a collaborative subspecialty of Gastroenterology that is dedicated to the unique needs of individuals with or at risk of cancer, with a focus on maintaining and man...

Delighted to share our thoughts on the emerging discipline of #oncogastroenterology in @natrevgastrohep.nature.com

#CUHKMedicine
#GIoncology #oncology

www.nature.com/articles/s41...

Alcohol‐Attributable Cancer: Update From the Global Burden of Disease 2021 Study The global burden of alcohol-attributable cancer in 2021 is increasing in the past two decades.

Happy to share our latest study on alcohol-attributable cancer. From 2000 to 2021, although the ASDR from alcohol-attributable cancer declined, the total number of deaths continued to rise. Efforts needed to address!

#APT #CUHKmedicine #GIoncology

onlinelibrary.wiley.com/doi/10.1111/...

Recent Cancer Control study validates the CGMH nomogram for predicting survival in metastatic #PancreaticCancer patients treated with nal-IRI + 5-FU/LV. A tool for personalized care in real-world settings.
#Oncology #CancerResearch #GIoncology #RealWorldData #PrecisionMedicine

Grateful to #kevinvanderjeught for the opportunity to visit the powerhouse #GIoncology program at #umiami Sylvester cancer center @drjashdatta.bsky.social #nipunmerchant

April is Esophageal Cancer Awareness Month - OncoDaily April is Esophageal Cancer Awareness Month / Adenocarcinoma, cancer, esophageal cancer, Esophageal Cancer Awareness Month, GI oncology, Headlines, OncoDaily,

April is Esophageal Cancer Awareness Month

oncodaily.com/blog/esophag...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EsophagealCancer #Adenocarcinoma #GIOncology

Laura Vater: A few reminders from a GI oncologist during colorectal cancer awareness month - OncoDaily Laura Vater: A few reminders from a GI oncologist during colorectal cancer awareness month / cancer, Colorectal Cancer Awareness Month, GI oncology, Laura

A few reminders from a GI oncologist during colorectal cancer awareness month - Laura Vater
@doclauravater.bsky.social

oncodaily.com/blog/255561

#Cancer #GIOncology #Oncologist #ColorectalCancer #CancerAwareness #Medicine #Health #Oncology #OncoDaily

Udhayvir Grewal: Poorly differentiated GEP carcinomas should be treated as adenocarcinomas - OncoDaily Udhayvir Grewal: Poorly differentiated GEP carcinomas should be treated as adenocarcinomas / adenocarcinomas, cancer, gastroenteropancreatic carcinoma, GEP

Poorly differentiated GEP carcinomas should be treated as adenocarcinomas - Udhayvir Grewal
@ugrewalmd.bsky.social

oncodaily.com/opinion/udha...

#Cancer #CancerTreatment #CancerResearch #Adenocarcinomas #GIOncology #Medicine #Health #Oncology #OncoDaily

Just wrapped up an incredible @binaytara.bsky.social GI Oncology Summit in Honolulu! Thanks to Dr. Teruo Yamauchi for his keynote on cancer care access and Dr. David Zhen of @fredhutch.bsky.social for his leadership. #CancerCare #GIONcology #Hawaii

Counting down the days to our Ohio State #GIOncology Symposium @osucccjames.bsky.social We are excited to welcome our guest speaker Dr Eileen O’Reilly. Registration is still open ccme.osu.edu/continuing-m...

Quite definitive conclusion from the ESOPEC trial favoring perioperative FLOT chemotherapy in locally advanced esophageal adenocarcinoma now out in @nejm.org

This can guide more refined patient selection more than a decade after the publication of CROSS

#MedSky #OncSky #GastroSky #GIOncology

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results - Nature Medicine In the largest study so far of CAR T cells in patients with solid tumors, autologous CLDN18.2-targeting CAR T cell therapy was well tolerated in patients with advanced CLDN18.2-positive gastrointestin...

Want to learn more about cell therapy in GI cancers? Check out the final results of this CLDN18.2 #CARTcells (CT041) trial, published during ASCO 2024 and just discussed at #GI25 #NatureMedicine #OncSky #GI25 #GIOncology
www.nature.com/articles/s41...

Erman Akkus: Understanding the BRAF pathway - OncoDaily Erman Akkus: Understanding the BRAF pathway / Biliary tract cancer, BRAF pathway, cancer, cholangiocarcinoma, Erman Akkus, ESMO Gastrointestinal Oncology, GI

Understanding the BRAF pathway - Erman Akkus
@ermanakkus.bsky.social

oncodaily.com/science/erma...

#BiliaryTract #Cancer #BRAFpathway #Cancer #Medicine #Cholangiocarcinoma #ESMO #GastrointestinalOncology #GIOncology #OncoDaily #Oncology #Health

Rachna Shroff: Amplifying women in GI Oncology - OncoDaily Rachna Shroff: Amplifying women in GI Oncology / Alwu Ruth He, Aparna Kalyan, Arizona Cancer Center, Bio Ascend, cancer, Cathy Eng, GI oncology, Kristen

Amplifying women in GI Oncology - Rachna Shroff
@rachnatshroff.bsky.social

oncodaily.com/blog/225567

#GIOncology #Medicine #Health #Oncology #OncoDaily #Cancer

#CancerCare #CancerResearch #CancerPrevention #CancerAwareness #GlobalOncology #CancerCommunity #GIOncology #OncologyCare #OncologyEducation #PatientAdvocacy #CancerSupport #SurvivorStrong #CancerWarrior #CancerFighters #WeFightCancer #OncologyLeaders #GlobalCancerMovement #HealthEquity